StockNews.AI
TECH
StockNews.AI
5 days

ScaleReady Announces Award of a G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory

1. Gates Institute receives $300,000 G-Rex Grant for CAR T-cell manufacturing. 2. The grant supports efficient cell and gene therapy manufacturing approaches. 3. ScaleReady has invested over $40M in G-Rex Grant products. 4. Bio-Techne collaborates on enhancing G-Rex Bioreactors for efficient manufacturing. 5. LEAN Cell & Gene program promotes waste reduction in cell therapy processes.

9m saved
Insight
Article

FAQ

Why Bullish?

This investment in advanced CGT technology may boost Bio-Techne's market position. Historical instances show that collaboration and funding in biotech often leads to stock price gains, e.g., Moderna's rise after securing grants for vaccine development.

How important is it?

The grant signifies strong backing for CGT development, likely increasing investor confidence in TECH and related sectors. The article highlights innovation and collaboration, key motivators for investors in biotechnology.

Why Long Term?

Technological advancements in CGT can positively influence future revenue. Innovations in this space tend to have lasting effects as therapies progress towards commercialization.

Related Companies

BIOCMRNAEDIT
, /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that the Translational Sciences Laboratory at Gates Institute, a leading contract development and manufacturing organization (CDMO) based at the University of Colorado Anschutz Medical Campus, has been awarded a $300,000 G-Rex® Grant to develop a modular G-Rex centric CAR T-cell manufacturing platform. "We are grateful for the generous G-Rex Grant funding, which will support the development of efficient and adaptable manufacturing approaches for our cell and gene therapy (CGT) programs," said Dr. Veena Krishnamoorthy, Director of Translational Sciences at the Gates Institute. "The scalable and modular nature of the G-Rex platform aligns with our goals to optimize use of space, capital, and personnel while maintaining cell health and quality. We appreciate the support from Wilson Wolf and Bio-Techne in advancing our work and the broader CGT field." "We are pleased to award G-Rex Grant funding to the Gates Institute, a leader in bridging the academic world of discovery with clinical application to advance a diverse portfolio of innovative cell therapies for devastating cancers and rare diseases. It's an honor to support the Gates Institute's important contributions to the field of cell and gene therapy." said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. The G-Rex Grant will support a structured Design of Experiments (DoE) to optimize key CAR-T cell manufacturing steps by systematically evaluating critical variables. The resulting data will continue to define and optimize how process conditions impact product attributes, enabling the Gates Institute to offer a broad range of manufacturing options within standardized, well-characterized design spaces for novel cell and gene therapies. As part of the G-Rex Grant, the Gates Institute will also receive early access to CellReady's G-CAR-TTM, a standardized CAR-T drug product manufacturing operation conceived of by CellReady, the world's first and only G-Rex CDMO.  G-CAR-TTM is ideal for high-throughput, low-cost manufacturing. ScaleReady's G-Rex Grant Program has authorized over $40M of products at no cost to grant recipients with the goal of advancing the state of cell and gene-modified cell therapy (CGT) development and manufacturing. Individual Grant Awards are worth up to $300,000.  G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. Importantly, ScaleReady has just introduced yet another FREE program to accelerate the universal presence of highly efficient and scalable CGT manufacturing. Under this program, ScaleReady has partnered with Hanson Wade to launch an event series called LEAN Cell & GeneTM.  All CGT entities are invited to attend and will learn how to systematically identify and eliminate waste, stabilize business operations, increase drug product quality and supply, and develop a LEAN approach to cell and gene therapy development and manufacturing. For more information about LEAN Cell & GeneTM, please use this link to register for the free event series. About Gates InstituteGates Institute is a world-class translational research institute with biomanufacturing capabilities. Based at the University of Colorado Anschutz Medical Campus, the institute is part of a rich biomedical ecosystem, enabling the development of life-saving treatments for a host of diseases at unmatched speed and scope. Gates Institute brings together and supports researchers and clinicians who specialize in regenerative, cell and gene therapies, accelerating their discoveries from concepts to cures. About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact [email protected]. About Wilson Wolf ManufacturingWilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing.  This is being accomplished through its fully scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate Development[email protected]612-656-4416 About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. SOURCE Bio-Techne Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News